Protalix BioTherapeutics (PLX) Capital Expenditures (2010 - 2026)
Protalix BioTherapeutics (PLX) recorded quarterly Capital Expenditures of $286000.0 in Q1 2026, up 133.03% quarter-over-quarter from -$866000.0 in Q4 2025, and down 33.02% on a YoY basis from $427000.0 in Q1 2025.
Protalix BioTherapeutics (PLX) Capital Expenditures (2010 - 2026) Analysis & Trends
Protalix BioTherapeutics' Capital Expenditures history runs 17 years deep, the most recent figure standing at $286000.0 for Q1 2026.
- In Q1 2026, Capital Expenditures fell 33.02% year-over-year to $286000.0; the TTM figure through Mar 2026 stood at $228000.0 (up 174.7% YoY), while the FY2025 annual figure was $369000.0, up 45.28% from the prior year.
- Capital Expenditures was $286000.0 for Q1 2026 at Protalix BioTherapeutics, up from -$866000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $736000.0 in Q3 2024 to a low of -$866000.0 in Q4 2025.
- Historically, Capital Expenditures has averaged $98000.0 across 5 years, with a median of $229000.0 in 2022.
- The sharpest annual moves came in 2023 and 2024: Capital Expenditures soared 682.26% in 2023, then plunged 333.82% in 2024.
- A 5-year view of Capital Expenditures shows it stood at -$62000.0 in 2022, then jumped by 682.26% to $361000.0 in 2023, then slumped by 267.04% to -$603000.0 in 2024, then plunged by 43.62% to -$866000.0 in 2025, then jumped by 133.03% to $286000.0 in 2026.
- The last three Capital Expenditures figures came in at $286000.0 (Q1 2026), -$866000.0 (Q4 2025), and $498000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 133.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -63,220.27 |
| 10 | Protalix BioTherapeutics | 176.47 Mn | 165.67 Mn | 29.62 Mn | 286,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 286,000.00 |
| Mar 31, 2026 | 286,000.00 |
| Dec 31, 2025 | -866,000.00 |
| Dec 31, 2025 | -866,000.00 |
| Sep 30, 2025 | 498,000.00 |
| Sep 30, 2025 | 498,000.00 |
| Jun 30, 2025 | 310,000.00 |
| Jun 30, 2025 | 310,000.00 |
| Mar 31, 2025 | 427,000.00 |
| Mar 31, 2025 | 427,000.00 |
| Dec 31, 2024 | -603,000.00 |
| Dec 31, 2024 | -603,000.00 |
| Sep 30, 2024 | 736,000.00 |
| Sep 30, 2024 | 736,000.00 |
| Jun 30, 2024 | -477,000.00 |
| Jun 30, 2024 | -477,000.00 |
| Mar 31, 2024 | 598,000.00 |
| Mar 31, 2024 | 598,000.00 |
| Dec 31, 2023 | 361,000.00 |
| Dec 31, 2023 | 361,000.00 |